The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
Criswell
Lindsey A
LA
Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA, USA.
Lum
Raymond F
RF
Turner
Kevin N
KN
Woehl
Blanche
B
Zhu
Yuanqing
Y
Wang
Jinyi
J
Tiwari
Hemant K
HK
Edberg
Jeffrey C
JC
Kimberly
Robert P
RP
Moreland
Larry W
LW
Seldin
Michael F
MF
Bridges
S Louis
SL
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D000068800:Etanercept; D005260:Female; D020022:Genetic Predisposition to Disease; D006684:HLA-DR Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008233:Lymphotoxin-alpha / Q000235:genetics*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011110:Polymorphism, Genetic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
D018501:Antirheumatic Agents; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007074:Immunoglobulin G; D008233:Lymphotoxin-alpha; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D008727:Methotrexate